Viralytics (OTCMKTS: VRACY) is one of 32 public companies in the “Commercial physical research” industry, but how does it compare to its peers? We will compare Viralytics to similar businesses based on the strength of its valuation, institutional ownership, risk, profitability, analyst recommendations, earnings and dividends.
Valuation & Earnings
This table compares Viralytics and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Viralytics||$4.88 million||-$9.26 million||-32.00|
|Viralytics Competitors||$806.43 million||$48.21 million||10.80|
This is a breakdown of current ratings and recommmendations for Viralytics and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Commercial physical research” companies have a potential upside of 12.00%. Given Viralytics’ peers higher probable upside, analysts clearly believe Viralytics has less favorable growth aspects than its peers.
Risk & Volatility
Viralytics has a beta of -6.1, indicating that its share price is 710% less volatile than the S&P 500. Comparatively, Viralytics’ peers have a beta of 3.22, indicating that their average share price is 222% more volatile than the S&P 500.
This table compares Viralytics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
46.4% of shares of all “Commercial physical research” companies are owned by institutional investors. 16.3% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Viralytics peers beat Viralytics on 7 of the 10 factors compared.
Viralytics Company Profile
Viralytics Limited, a biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies in Australia and internationally. The company's lead investigational product is CAVATAK, a proprietary formulation of an oncolytic common cold virus that is in Phase Ib clinical trials for the treatment of melanoma, and lung and bladder cancer; Phase II clinical trials for the treatment of late stage melanoma; and in pre-clinical studies for the treatment of prostate and breast cancer, multiple myeloma, pancreatic cancer, malignant glioma, acute myeloid leukemia, and chronic lymphocytic leukemia. It is also developing EVATAK to treat ovarian, prostate, and gastric cancer. The company was formerly known as Psiron Ltd. and changed its name to Viralytics Limited in December 2006. Viralytics Limited is headquartered in Sydney, Australia.
Receive News & Ratings for Viralytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viralytics and related companies with MarketBeat.com's FREE daily email newsletter.